Patents Assigned to GRÜNENTHAL GMBH
  • Tamper resistant dosage form comprising inorganic salt
    Patent number: 10300141
    Abstract: A pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, wherein the dosage form contains a pharmacologically active ingredient (A); an inorganic salt (B); and a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (C) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (A) is present in a controlled-release matrix comprising the inorganic salt (B) and the polyalkylene oxide (C) and wherein, under in vitro conditions, the release profile of the pharmacologically active ingredient (A) from the matrix comprises at least a time interval during which the release follows zero order kinetics.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 28, 2019
    Assignee: GRÜNENTHAL GMBH
    Inventor: Lutz Barnscheid
  • NOVEL CRYSTALLINE FORMS
    Publication number: 20190144474
    Abstract: Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Application
    Filed: November 12, 2018
    Publication date: May 16, 2019
    Applicant: GRUNENTHAL GMBH
    Inventors: Mazen HANNA, Ning SHAN, David R. WEYNA, Miranda L. CHENEY
  • ABUSE-PROOFED ORAL DOSAGE FORM
    Publication number: 20190142767
    Abstract: The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
    Type: Application
    Filed: January 9, 2019
    Publication date: May 16, 2019
    Applicant: GRUNENTHAL GMBH
    Inventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
  • TAMPER-RESISTANT DOSAGE FORM CONTAINING ONE OR MORE PARTICLES
    Publication number: 20190142757
    Abstract: The invention relates to a tamper-resistant pharmaceutical dosage form comprising one or more particles, wherein each of said one or more particles comprises a pharmacologically active ingredient and a physiologically acceptable polymer; has a breaking strength of at least 300 N; has a weight of at least 2 mg; and optionally, comprises a film-coating; wherein the total weight of the pharmaceutical dosage form is greater than the total weight of said one or more particles.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: LUTZ BARNSCHEID, ANJA GEIßLER, KLAUS WENING, JANA PÄTZ
  • REINFORCED PHARMACEUTICAL DOSAGE FORM
    Publication number: 20190133956
    Abstract: The invention relates to a reinforced pharmaceutical dosage form comprising a pharmacologically active ingredient and fibers. The reinforced pharmaceutical dosage form is tamper-resistant and thus useful for the avoidance of drug abuse or misuse. The invention also relates to the preparation of such dosage forms and their use in therapy.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 9, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Marcel HAUPTS, Klaus WENING, Carmen STOMBERG, Siegfried EBNER
  • TAMPER-RESISTANT TABLET PROVIDING IMMEDIATE DRUG RELEASE
    Publication number: 20190125680
    Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of coated particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a physiologically acceptable polymer, preferably a polyalkylene oxide; and form a discontinuous phase within the matrix material; which preferably provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.; and method of using said tablet to treat pain and other conditions.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Applicant: Grünenthal GmbH
    Inventors: Sebastian SCHWIER, Marcel HAUPTS, Lutz BARNSCHEID, Jana PÄTZ
  • 6-membered cyclic amines or lactames substituted with urea and phenyl
    Patent number: 10265310
    Abstract: The present invention relates to a compound according to general formula (I) which acts as a modulator of FPR2 and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by FPR2.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: April 23, 2019
    Assignee: GrÜNENTHAL GMBH
    Inventors: Florian Jakob, Sonja Nordhoff, David Rider, Markus Wagener, Gregor Bahrenberg, Torsten Dunkern
  • MODIFIED RELEASE ABUSE DETERRENT DOSAGE FORMS
    Publication number: 20190110992
    Abstract: The invention relates to a pharmaceutical dosage form for oral administration comprising a pharmacologically active compound; wherein a portion of said pharmacologically active compound is contained in a multitude of immediate release particles providing immediate release of the pharmacologically active compound; wherein another portion of said pharmacologically active compound is contained in at least one controlled release particle providing controlled release of the pharmacologically active compound; and wherein the breaking strength of each of the immediate release particles and/or of the at least one controlled release particle is at least 300 N.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Applicant: Grünenthal GmbH
    Inventors: Carmen Stomberg, Harald Paul, Klaus Wening, Sebastian Schwier
  • TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
    Publication number: 20190111050
    Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: KLAUS WENING, ANJA GEIßLER- FICHTNER, JANA DENKER, LUTZ BARNSCHEID
  • 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES
    Publication number: 20190106430
    Abstract: The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: December 7, 2018
    Publication date: April 11, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Florian JAKOB, Achim KLESS, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER, Klaus SCHIENE, Anita WEGERT
  • 3-(CARBOXYETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES
    Publication number: 20190100497
    Abstract: The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: December 3, 2018
    Publication date: April 4, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Florian JAKOB, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
  • CRYSTALLIZATION METHOD AND BIOAVAILABILITY
    Publication number: 20190083407
    Abstract: Preparation and in vitro and in vivo characterization of novel forms of active pharmaceutical ingredients, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Application
    Filed: March 15, 2018
    Publication date: March 21, 2019
    Applicant: GRUNENTHAL GMBH
    Inventor: Mazen HANNA
  • Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
    Publication number: 20190062263
    Abstract: A hitherto unknown crystalline form of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
    Type: Application
    Filed: October 26, 2018
    Publication date: February 28, 2019
    Applicant: Grünenthal GmbH
    Inventors: Andreas FISCHER, Helmut BUSCHMANN, Michael GRUSS, Dagmar LISCHKE
  • TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
    Publication number: 20190054081
    Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.
    Type: Application
    Filed: October 22, 2018
    Publication date: February 21, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Klaus Wening, Anja Geissler-Fichtner, Jana Denker, Lutz Barnscheid
  • Crystallization method and bioavailability
    Patent number: 10195218
    Abstract: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: February 5, 2019
    Assignee: GRUNENTHAL GMBH
    Inventor: Mazen Hanna
  • ABUSE-PROOFED DOSAGE FORM
    Publication number: 20190029976
    Abstract: The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
    Type: Application
    Filed: September 28, 2018
    Publication date: January 31, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIĆ
  • FLOATING PHARMACEUTICAL DOSAGE FORM
    Publication number: 20190015344
    Abstract: The invention relates to a pharmaceutical dosage form having a density below the density of gastric fluid, wherein the dosage form comprises a pharmacologically active ingredient and a cavity. The invention also relates to a process for the preparation of said dosage form comprising a three-dimensional printing step.
    Type: Application
    Filed: September 18, 2018
    Publication date: January 17, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Klaus WENING, Carmen STOMBERG, Marcel HAUPTS
  • COMBINATION OF DRUGS HAVING DIFFERENT POTENCY
    Publication number: 20190015343
    Abstract: The invention relates to a three-dimensionally printed pharmaceutical dosage form comprising a first pharmacologically active ingredient and a second pharmacologically active ingredient; wherein the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient in the pharmaceutical dosage form is within the range of from 10,000:1 to 1:1. The invention also relates to a process for the preparation of such pharmaceutical dosage form by three-dimensional printing, preferably by fused deposition modeling.
    Type: Application
    Filed: September 18, 2018
    Publication date: January 17, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Carmen STOMBERG, Klaus WENING, Marcel HAUPTS
  • 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES
    Publication number: 20190016685
    Abstract: The invention relates to 1,3-diaza-spiro-[3.4]-octane derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.
    Type: Application
    Filed: July 12, 2018
    Publication date: January 17, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Paul RATCLIFFE, Ingo KONETZKI, Nikolay SITNIKOV, Thomas KOCH, Ruth JOSTOCK
  • ABUSE-PROOFED DOSAGE FORM
    Publication number: 20190008849
    Abstract: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.
    Type: Application
    Filed: July 11, 2018
    Publication date: January 10, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Elisabeth ARKENAU MARIC, Johannes BARTHOLOMAEUS, Heinrich KUGELMANN